Becton Dickinson announced a collaboration agreement with Hamilton, a global manufacturer of laboratory automation technology, to develop automated applications together with robotics-compatible reagent kits to enable greater standardization and reduced human error when conducting large-scale single-cell multiomics experiments. As a result of the collaboration, BD aims to deliver a suite of BD Rhapsody Single-Cell Analysis Library Preparation Reagent Kits that can be performed on the Hamilton Microlab NGS STAR robotic liquid-handling platform. The combination will automate steps, including pipetting and thermal cycling, to produce DNA samples or “libraries” that are ready for genetic sequencing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BDX:
- Becton Dickinson sees shifting of $30M of flu testing revenue from Q1
- Becton Dickinson backs FY adjusted EPS view $12.70-$13.00, consensus $12.84
- Accelerate Diagnostics price target lowered to $2 from $5 at Craig-Hallum
- Becton Dickinson to pay $85M in infusion pump settlement
- Becton Dickinson granted exclusive license by Bactiguard for Foley catheters